Abstract
Our understanding of AATD has improved significantly since 1963 when the condition was first described. We have learnt a lot about the structure and function of the protein, the epidemiology of AATD, the identification and characterization of rare AATD and null variants, the factors involved in regulating gene expression and the variability in phenotype with respect to the two most commonly associated disease conditions affecting the lungs and the liver. Some of the important unanswered questions that will guide further future research are highlighted.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
